US stock futures remained relatively stable as investors anticipated upcoming earnings reports from significant companies.
Why it matters: The intersection of earnings reports and geopolitical developments will continue to influence market sentiment in the coming weeks. Investors must navigate these uncertain times, weighing the positive corporate earnings against potential trade disruptions.
The details:
- The S&P 500 and the Nasdaq both held steady at the start of the week, buoyed by solid earnings reports from companies such as Domino’s Pizza, Cleveland-Cliffs, and Verizon.
- Of the more than 60 S&P 500 companies that have reported so far, over 85% have exceeded analysts’ estimates, according to FactSet data.
- Analysts had anticipated a 6.7% increase in earnings for the second quarter for S&P 500 companies, with major gains driven by large technology firms, as per LSEG I/B/E/S data.
- Companies like Philip Morris International, Coca-Cola, and Lockheed Martin are expected to report their earnings before the market opens, with highly anticipated midweek reports from Tesla and Alphabet.
At 6 a.m. ET, futures linked to the blue-chip Dow were unchanged, while S&P 500 futures slipped 0.11% and Nasdaq futures dropped 0.27%.
Meanwhile, Federal Reserve Chairman Jerome Powell is scheduled to speak at a conference in Washington DC as the stock market opens, which could also influence market sentiment.
In corporate news:
- Goldman Sachs had previously engaged in discussions for a roughly $25 billion takeover of wealth management firm Northern Trust and nearly closed a $6 billion deal for Cliffwater.
- NXP Semiconductors’ second-quarter results surpassed analysts’ forecasts, while Steel Dynamics’ results fell short.
- Zions Bancorp exceeded Wall Street’s estimates with its second-quarter earnings per share.
In a significant development, Sarepta Therapeutics announced it would pause all shipments of its Elevidys gene therapy in the United States following the death of a muscular dystrophy patient who had received a different experimental treatment. Initially, the company had refused to comply with an FDA request for a pause.
What’s next: As these corporate events unfold and earnings reports are released, investors will closely watch for signs that could indicate broader economic trends and corporate health.
Recent from X
Health Care sector's forward P/E is almost at a record discount vs. S&P 500's forward P/E pic.twitter.com/i80208TCjW
— Liz Ann Sonders (@LizAnnSonders) July 22, 2025
S&P 600’s forward P/E has rebounded sharply of late but still looks tame relative to history pic.twitter.com/leCEonhanI
— Liz Ann Sonders (@LizAnnSonders) July 21, 2025
#MarketAlert | Stocks stir ahead of Q1 earnings — pressure on some, buzz around others 📉📈#Q1Earnings #StockMarket #EarningsSeason #MarketBuzz pic.twitter.com/cnMd54u7qB
— ET NOW (@ETNOWlive) July 22, 2025
Stock Market today: Sensex up 250 pts, Nifty above 25150; Zomato zooms 10%https://t.co/QGNXg4kBSN pic.twitter.com/Zc0qOtHYaC
— ET NOW (@ETNOWlive) July 22, 2025